Immunmodulatorische Stufentherapie der Multiplen Sklerose
Tóm tắt
Từ khóa
Tài liệu tham khảo
Multiple Sclerosis Therapy Consensus Group, MSTCG (2004) Escalating immunotherapy of multiple sclerosis–new aspects and practical application. J Neurol 251: 1329–1339
Diener HC (2003) Multiple Sklerose. Leitlinien der Deutschen Gesellschaft für Neurologie, 2. Aufl. Thieme, Stuttgart, S 210–215
MSTKG (2002) Immunmodulatorische Stufentherapie der Multiplen Sklerose—Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73: 556–563
Goodin D et al. (2002) Disease modifying therapies in multiple sclerosis—Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS councel for clinical practice guidelines. Neurology 58: 169–178
McDonald W et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127
Dalton C et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive o multiple sclerosis. Ann Neurol 52: 47–53
Tintore M et al. (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60: 27–30
Polman CH, Wolinsky JS, Reingold SC (2005) Multiple sclerosis diagnostic criteria: three years later. Mult Scler 11: 5–12
Polman CH et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. Ann Neurol 58: 840–846
Wiendl H, Kieseier BC, Gold R et al. (2006) Revision der neuen McDonalds Kriterien zur Diagnose einer MS. Nervenarzt 77: 1235–1245
Berger T et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139–145
Gaertner S et al. (2004) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63: 2381–2383
Lampasona V et al. (2004) Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62: 2092–2094
Rauer S et al. (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77: 739–742
Lennon VA et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112
Nakashima I, Fujihara K, Miyazawa I et al. (2006) Clinical and MRI features of Japanese MS patients with NMO-IgG. J Neurol Neurosurg Psychiatry 77:1073–1075
Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L (2001) Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124: 2162–2168
Kallmann B et al. (2006) Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 12: 58–65
Kappos L, Polman CH, Freedman MS et al. (2006) Treatment with interferon beta-1b delays conversion to clinically and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–9124
Anonymus (2006) Europäische Kommission genehmigt Aktualisierung der therapeutischen Indikation für Rebif®. http://www.serono.com/content/media/downloads/2006/20060710_de.pdf
Rio J et al. (2005) Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252: 795–800
Kinkel RP et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678–684
Pohl D et al. (2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 64: 888–890
Ghezzi A et al. (2005) Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 11: 420–424
Tenembaum SN, Segura MJ (2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67: 511–3
Banwell B et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66: 472–476
Sandberg-Wollheim M et al. (2005) Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65: 802–806
Boskovic R et al. (2005) The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65: 807–811
Hartung HP (2005) Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 252 (Suppl 3): iii44–iii50
Clanet M et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59: 1507–17
Clanet M et al. (2004) Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 10: 139–144
Freedman MS et al. (2005) Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11: 41–45
Vartanian T (2003) An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 25: 105–118
Panitch H et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506
Panitch H et al. (2005) Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 239: 67–74
Schwid SR et al. (2005) Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 62: 785–792
Durelli L et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316): 1453–1460
Koch-Henriksen N, Sorensen PS, Christensen T et al. (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66:1056–1060
Bertolotto A (2004) Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17: 241–246
Sorensen S et al. (2005) Guidelines on use of anti-IFN-beta antibody measurementsin multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12: 817–827
Sorensen S et al. (2005) Appearance and disappearance of neutralizing antibodies during interferon beta therapy. Neurology 65: 33–39
Sorensen S et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184–1191
Polman C et al. (2003) Neutralizingantibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60: 37–43
Francis GS, Rice GP, Alsop JC (2005) Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65: 48–55
Kappos L et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65: 40–47
Hemmer B et al. (2005) Immune response to immunotherapy: the role of neutralizing antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 4: 403–412
Ford CC et al. (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 12: 309–320
Johnson KP et al. (2005) Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 111: 42–47
Sindic CJ et al. (2005) Long-term follow up of glatiramer acetate compassionate use in Belgium. Acta Neurol Belg 105: 81–85
Vallittu AM et al. (2005) The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 112: 234–237
Flechter S et al. (2002) Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 197(1–2): 51–55
Khan O et al. (2001) A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7: 349–353
Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12: 425–431
Cohen J et al. (2006) Results of a Randomized, Double-Blind, Parallel-Group Study Assessing Safety and Efficacy of 40 mg vs. 20 mg of Glatiramer Acetate on MRI-Measured Disease Activity in RRMS. Neurology 67: 185
Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253: 1160–1164
Ziemssen T (2004) Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 541: 111–134
Aharoni R et al. (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 102: 19045–19050
Khan O et al. (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11: 646–651
Filippi M, Wolinsky JS, Comi G (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 5: 213–220
Yednock T A et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63–66
Theien BE et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107: 995–1006
Miller DH et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15–23
Rudick RA et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923
Polman CH et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910
Yousry TA et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924–933
Khalili K, White MK (2006) Human demyelinating disease and the polyomavirus JCV. Mult Scler 12: 133–142
Biogen Idec GmbH (2006) Arzt-Information und Management-Leitlinien für Multiple Sklerose-Patienten, die Tysabri erhalten. http://www.biogenidec.de
Europäischen Arzneimittel Agentur (2006) Fachinformation TysabriTM300 mg Konzentrat. http://www.emea.eu.int
Ghalie R et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59: 909–913
Ghalie R et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8: 441–445
Scott LJ, Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18: 379–396
O’Connor W et al. (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62: 2038–2043
O’Connor W et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894–900
Kappos L et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140
Sipe JC (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5: 721–727
Markovic-Plese S et al. (2003) Longitudinal MRI study: the effects of azathioprinein MS patients refractory to interferon beta-1b. Neurology 60: 1849–1851
Pulicken M et al. (2005) Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 11: 169–174
Calabresi A et al. (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58: 314–317
Jeffery DR (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63(Suppl 6): S41–46
Smith DR et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11: 573–582
Jeffery DR et al. (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11: 296–301
Perini, et al. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis : A comparative study. J Neurol 253:1034–1040
Sorensen S (2003) Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Neurol Sci 24 (Suppl 4): S227–230
Achiron A et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61: 1515–1520
Hommes OR et al. (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364: 1149–1156
Sorensen S et al. (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63: 2028–33
Stangel M, Gold R (2005) Intravenous immunoglobulins in MS. Int MS J 12: 5–10
Achiron A et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251: 1133–1137
Haas J (2000) High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6 (Suppl 2): S18–20
Hartung H et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018–2025
Krapf H et al. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 65: 690–695
Massacesi L et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62: 1843–1847
Vermersch P, Stojkovic T, de Seze J (2005) Mycophenolate mofetil and neurological diseases. Lupus 14 (Suppl 1): s42–45
Vollmer T et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607–1608
Ruprecht K et al. (2004) Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63: 1081–1083
Lehmann HC et al. (2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63: 930–935
Tomassini V et al. (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253: 287–293
Filippi M et al. (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13: 313–325
Simon J et al. (2006) Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am J Neuroradiol 27: 455–461
Freedman MS et al. (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31: 157–168
Filippini G et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361: 545–552
Aaltonen U (2003) European Parliament resolution on Petition 842/2001 concerning the effects of discriminatory treatment afforded to persons with multiple sclerosis within the European Union (2003/2173(INI)). http://www3.europarl.eu.int/omk/omnsapir.so/cre?FILE=1218je&LANGUE=DE&LEVEL=DOC&NUMINT=4–006&LEG=L5
Flachenecker P, Zettl UK, Götze U et al. (2005) MS-Register in Deutschland: 1. Design und erste Ergebnisse der Pilotphase. Nervenarzt 76: 967–975
Thompson AJ (2002) Progress in neurorehabilitation in multiple sclerosis. Curr Opin Neurol 15: 267–270
Zettl UK, Tumani H (2005) Multiple sclerosis and cerebrospinal fluid. Blackwell, Oxford/UK